DS
MRNA icon

David Shaw’s Moderna MRNA Stock Holding History

David Shaw’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.75M Sell
24,951
-641,581
-96% -$33.2M ﹤0.01% 3317
2026
Q1 		$33.9M Sell
666,532
-4,516,227
-87% -$211M 0.02% 854
2025
Q4 		$153M Sell
5,182,759
-963,615
-16% -$26.2M 0.08% 271
2025
Q3 		$159M Sell
6,146,374
-1,317,181
-18% -$36.7M 0.09% 247
2025
Q2 		$206M Buy
7,463,555
+1,827,404
+32% +$48.1M 0.15% 144
2025
Q1 		$160M Buy
5,636,151
+3,867,436
+219% +$137M 0.14% 163
2024
Q4 		$73.5M Buy
1,768,715
+1,509,591
+583% +$72.2M 0.05% 426
2024
Q3 		$17.3M Buy
+259,124
New +$23.8M 0.01% 1087
2024
Q2 		– Sell
-48,022
Closed -$6.08M – 4708
2024
Q1 		$5.12M Sell
48,022
-314,155
-87% -$31.7M ﹤0.01% 1869
2023
Q4 		$36M Buy
362,177
+303,845
+521% +$25.6M 0.03% 605
2023
Q3 		$6.03M Sell
58,332
-20,175
-26% -$2.25M 0.01% 1662
2023
Q2 		$9.54M Sell
78,507
-189,573
-71% -$25.3M 0.01% 1377
2023
Q1 		$41.2M Sell
268,080
-298,928
-53% -$49.3M 0.04% 508
2022
Q4 		$102M Buy
567,008
+294,842
+108% +$48.2M 0.11% 198
2022
Q3 		$32.2M Buy
272,166
+245,352
+915% +$37.2M 0.04% 597
2022
Q2 		$3.83M Sell
26,814
-1,227,130
-98% -$175M ﹤0.01% 2459
2022
Q1 		$216M Buy
1,253,944
+240,949
+24% +$40.6M 0.2% 78
2021
Q4 		$257M Buy
1,012,995
+259,232
+34% +$75.8M 0.21% 72
2021
Q3 		$290M Sell
753,763
-920,545
-55% -$340M 0.26% 51
2021
Q2 		$393M Buy
1,674,308
+1,616,152
+2,779% +$289M 0.34% 40
2021
Q1 		$7.62M Sell
58,156
-3,051,745
-98% -$442M 0.01% 1550
2020
Q4 		$325M Buy
3,109,901
+2,343,772
+306% +$237M 0.29% 50
2020
Q3 		$54.2M Buy
766,129
+455,804
+147% +$31.8M 0.06% 387
2020
Q2 		$19.9M Buy
310,325
+262,490
+549% +$14.4M 0.02% 780
2020
Q1 		$1.43M Sell
47,835
-327,503
-87% -$7.53M ﹤0.01% 2445
2019
Q4 		$7.34M Buy
+375,338
New +$6.66M 0.01% 1431
2019
Q3 		– Sell
-25,128
Closed -$368K – 3940
2019
Q2 		$368K Buy
+25,128
New +$540K ﹤0.01% 3222

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

David Shaw's MRNA Position: Q2 2026 in Review

David Shaw reduced its Moderna (MRNA) stake by 96% in Q2 2026, selling an estimated $33.2M and leaving 24,951 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3317.

David Shaw first reported a position in MRNA in Q2 2019 and has held it in 27 quarters since. The position peaked at $393M in Q2 2021. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • David Shaw held 24,951 shares of Moderna worth $1.75M as of Q2 2026.
  • David Shaw sold 641,581 Moderna shares in Q2 2026, an estimated $33.2M.
  • Moderna made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3317 holding.
  • David Shaw first reported a position in Moderna in Q2 2019 and has held it in 27 quarters since.
  • David Shaw's Moderna position peaked at $393M in Q2 2021.
  • 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.